131 results
Page 6 of 7
6-K
EX-99.1
3x2jtw017hx01vi2k
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
6-K
EX-99.3
lfst3sdk10gp3
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
424B3
cww iyh7z5
4 Mar 21
Prospectus supplement
8:38am
6-K
EX-99.1
qhp5y06
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
6-K
EX-99.1
i8zc0z
20 Jan 21
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6:30am
424B4
53xu9y3 wdl
14 Jan 21
Prospectus supplement with pricing info
9:30am
F-1/A
88ervtxe2s0wp
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1
jh4q2n4 1rut
8 Jan 21
Registration statement (foreign)
4:58pm
DRS
lun3p
18 Dec 20
Draft registration statement
12:00am
6-K
EX-99.1
01tix2dcu3 g6jfw4z
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
EX-99.1
04a29nu74gxy0m9id
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
EX-99.1
nz1zu2c uy
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
EX-99.1
6isfs
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
EX-99.1
wh2ydir
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
EX-99.1
qr5gkg5k9ycmp d65p
19 Oct 20
Current report (foreign)
8:00am
6-K
EX-99.1
oe0t18iks0p2gfsq0cv
15 Sep 20
Current report (foreign)
8:31am
6-K
EX-99.1
a7vgdgp8ho
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
EX-99.1
4s0shp
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
EX-99.1
oebhlww b3
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
EX-99.1
emtf xs9jo
10 Jul 20
Current report (foreign)
9:46am